Formation of a factor increasing vascular permeability during electrical stimulation of the saphenous nerve in rats.
1 Increased vascular permeability following electric antidromic stimulation of the rat saphenous nerve was observed in the skin area supplied by the nerve, confirming previous results by other authors.2 The phenomenon was not affected by pretreatment of the rats with diphenhydramine, burimamide or their combination; atropine, methysergide, methysergide plus diphenhydramine, carboxypeptidase B, acetylsalicylic acid, indomethacin or methiazinic acid. It was partially reduced by previous injection of cellulose-sulphate, a kininogen-depleting agent.3 Perfusates from the subcutaneous tissue of the paw area supplied by the saphenous nerve contained permeability increasing activity as shown by intradermal tests in other rats. This activity was present in perfusates collected during nerve stimulation but not in those collected before stimulation. It was not destroyed by heating to 100 degrees C, or by alpha-chymotrypsin or trypsin.4 Bradykinin-like activity may appear later in the perfusates, depending on the intensity of the stimuli.5 It is concluded that following electrical antidromic stimulation of the saphenous nerve a permeability increasing factor is released, possibly from nerves. It is dialysable and can be distinguished from acetylcholine, histamine, 5-hydroxytryptamine, plasma kinins, substance P, prostaglandins and high molecular weight proteins. The increased vascular permeability induced by this factor leads to plasma exudation and activation of the kinin system.
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects*; D002268:Carboxypeptidases / Q000494:pharmacology; D002918:Chymotrypsin / Q000494:pharmacology; D003956:Dialysis; D004558:Electric Stimulation; D006632:Histamine / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007704:Kininogens / Q000494:pharmacology; D007705:Kinins / Q000494:pharmacology; D007866:Leg / Q000294:innervation*; D008297:Male; D009474:Neurons / Q000502:physiology*; D010477:Perfusion; D011453:Prostaglandins / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000494:pharmacology; D013194:Staining and Labeling; D013373:Substance P / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology
D007704:Kininogens; D007705:Kinins; D011453:Prostaglandins; D011506:Proteins; D012701:Serotonin; D013373:Substance P; D006632:Histamine; D002268:Carboxypeptidases; D002918:Chymotrypsin; D014357:Trypsin; D000109:Acetylcholine; D001241:Aspirin; D001920:Bradykinin; D007213:Indomethacin